Politi et al., 2008
So far, clinical trial data for elamipretide and bardoxolone underscore the viability of mechanism-driven therapies in treating OSrelated diseases ( Evidence about the role of mtROS has led to the development of MATs for therapeutic intervention in several diseases, including HTN -Figure 2 (Pool et al., 2021), whereas MitoTEMPO can scavenge mtROS, reduce oxidative damage to mitochondria, restore mitochondrial function, and help maintain normal cellular function ( 5.3 NADPH oxidases (NOXs) NOXs are the only known enzymes specifically responsible for generating ROS (Ogrunc et al., 2014)
It is to create a framework where the medication does what it is designed to do, and where you have clinical support every step of the way
When their body starts slowing down, its worth exploring whats out there to help them stay comfortable, mobile, and present for as long as possible
Chang X, Wang Z, Zhang J, et al
Movement: Walking promotes gut motility